IN BRIEF: PureTech Health says LYT-100 slows lung function decline
16th Dec 2024 14:35
PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Notes that deupirfenidone, also known as LYT-100, slows lung function decline in people with idiopathic pulmonary fibrosis as measured by forced vital capacity in a phase 2b trial. Toby Maher, professor of medicine & director of interstitial lung disease at Keck School of Medicine at the University of Southern California in Los Angeles, and lead investigator in the Elevate IPF trial, says: "Deupirfenidone has the potential to offer patients a highly effective and tolerable treatment option. These are extremely exciting results from a phase 2b trial, and I am very enthusiastic about the continued development of deupirfenidone." Read More